Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael C Sneller

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Blood|March 10, 2011
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaquesThomas A Waldmann, Enrico Lugli, Mario Roederer, et al.
Frontiers in Immunology|December 23, 2021
Rapid Emergence of T Follicular Helper and Germinal Center B Cells Following Antiretroviral Therapy in Advanced HIV DiseaseChun-Shu Wong, Clarisa M Buckner, Silvia Lucena Lage, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2022
Early human B cell signatures of the primary antibody response to mRNA vaccinationLela Kardava, Nicholas Rachmaninoff, William W Lau, et al.
The Lancet. Global Health|June 22, 2023
Pregnancy, pregnancy outcomes, and infant growth and development after recovery from Ebola virus disease in Liberia: an observational cohort studyMosoka P Fallah, Cavan Reilly, Collin Van Ryn, et al.
Nature|April 14, 2022
Prolonged viral suppression with anti-HIV-1 antibody therapyChristian Gaebler, Lilian Nogueira, Elina Stoffel, et al.
Science Translational Medicine|December 8, 2017
A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infectionMichael C Sneller, J Shawn Justement, Kathleen R Gittens, et al.
Nature Medicine|January 3, 2025
Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavirM Ali Rai, Jana Blazkova, Lela Kardava, et al.
AIDS (London, England)|June 15, 2021
Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteriaJesse Fajnzylber, Radwa Sharaf, John N Hutchinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancerKevin C Conlon, Enrico Lugli, Hugh C Welles, et al.
Medrxiv : the Preprint Server for Health Sciences|July 16, 2021
Pre-vaccination and early B cell signatures predict antibody response to SARS-CoV-2 mRNA vaccineLela Kardava, Nicholas Rachmaninoff, William W Lau, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Blood|March 10, 2011
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaquesThomas A Waldmann, Enrico Lugli, Mario Roederer, et al.
Frontiers in Immunology|December 23, 2021
Rapid Emergence of T Follicular Helper and Germinal Center B Cells Following Antiretroviral Therapy in Advanced HIV DiseaseChun-Shu Wong, Clarisa M Buckner, Silvia Lucena Lage, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2022
Early human B cell signatures of the primary antibody response to mRNA vaccinationLela Kardava, Nicholas Rachmaninoff, William W Lau, et al.
The Lancet. Global Health|June 22, 2023
Pregnancy, pregnancy outcomes, and infant growth and development after recovery from Ebola virus disease in Liberia: an observational cohort studyMosoka P Fallah, Cavan Reilly, Collin Van Ryn, et al.
Nature|April 14, 2022
Prolonged viral suppression with anti-HIV-1 antibody therapyChristian Gaebler, Lilian Nogueira, Elina Stoffel, et al.
Science Translational Medicine|December 8, 2017
A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infectionMichael C Sneller, J Shawn Justement, Kathleen R Gittens, et al.
Nature Medicine|January 3, 2025
Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavirM Ali Rai, Jana Blazkova, Lela Kardava, et al.
AIDS (London, England)|June 15, 2021
Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteriaJesse Fajnzylber, Radwa Sharaf, John N Hutchinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancerKevin C Conlon, Enrico Lugli, Hugh C Welles, et al.
Medrxiv : the Preprint Server for Health Sciences|July 16, 2021
Pre-vaccination and early B cell signatures predict antibody response to SARS-CoV-2 mRNA vaccineLela Kardava, Nicholas Rachmaninoff, William W Lau, et al.
Pageof 6